Core Insights - PetVivo Animal Health, Inc. has entered into a Vendor Partner Agreement with Veterinary Growth Partners to promote its innovative veterinary products [1][5] - The agreement aims to enhance the accessibility and adoption of PetVivo's flagship products, Spryng with OsteoCushion Technology and PrecisePRP, among veterinary practices [2][5] Company Overview - PetVivo Holdings, Inc. is focused on the commercialization of biomedical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment solutions [6][7] - The company has a robust pipeline of products protected by twelve patents and six trade secrets, including Spryng and PrecisePRP [7] Product Details - Spryng with OsteoCushion Technology is an intra-articular injectable device designed to manage joint pain and improve joint mechanics in animals [3] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product that provides a consistent dose of 4 billion platelets per vial, designed for easy use by veterinarians [4] Partnership Impact - The collaboration with Veterinary Growth Partners is expected to expand national availability and enhance purchasing efficiency for veterinary practices seeking non-pharmaceutical solutions [5][8] - Veterinary Growth Partners supports over 7,300 veterinary members across the U.S., providing a significant network for PetVivo's products [1][2]

Core Insights - PetVivo Animal Health has launched three new continuing education courses aimed at veterinary professionals, focusing on osteoarthritis, joint injection techniques, and regenerative modalities for small animals and equines [1][4]. Course Offerings - The courses are RACE-approved and provide 1.0 credit hour each, developed by practicing veterinarians with expertise in surgery and rehabilitation [2][3]. - Course topics include: - An introductory overview of osteoarthritis pathophysiology and multimodal management strategies [7]. - Advanced exploration of joint injections, including biomechanics and treatment modalities [7]. - Examination of equine osteoarthritis and the scientific rationale for regenerative therapies [7]. Company Commitment - PetVivo Animal Health emphasizes a commitment to advancing regenerative medicine in veterinary practice, focusing on disease-modifying potential and clinical applications [4]. - The courses are offered at no cost to veterinarians, veterinary technicians, and allied professionals, reflecting the company's dedication to education and professional development [5]. Company Overview - PetVivo Animal Health is a subsidiary of PetVivo Holdings, Inc., specializing in veterinary medical devices and regenerative therapies for managing osteoarthritis and joint-related conditions [6]. - The company's product portfolio includes Spryng with OsteoCushion Technology and PrecisePRP, aimed at providing long-term joint support and improving animal mobility and quality of life [6].

Summary of PetVivo Holdings Conference Call Company Overview - **Company Name**: PetVivo Holdings - **Ticker Symbol**: PETV - **Market Focus**: Companion animal veterinary care market, valued at approximately $11 billion [2][19] Core Products - **Spryng with OsteoCushion Technology**: A veterinary medical device designed to restore joint mechanics and address osteoarthritis in animals. It is classified as a human medical device, allowing it to bypass FDA review for veterinary use [2][8]. - **PrecisePRP**: An allogenic freeze-dried platelet-rich plasma product, the only FDA-reviewed product for safety that does not require blood drawing from the animal [2][17]. Market Dynamics - **Osteoarthritis Prevalence**: Approximately 80% of dogs will develop osteoarthritis by age eight, with symptoms often starting as early as three to four years old [4]. - **Current Treatment Limitations**: Existing treatments primarily mask symptoms rather than address the root cause, leading to potential long-term damage [5][12]. Competitive Advantages - **Unique Mechanism of Action**: Spryng addresses the underlying issues of joint degradation rather than just alleviating pain, providing a longer-lasting solution (up to 12 months) compared to other treatments [6][8]. - **Cost-Effectiveness**: Spryng's pricing ranges from $600 to $1,200 per injection, which is competitive compared to monthly treatments like Librela costing around $150 [31][32]. - **Strong Intellectual Property Portfolio**: PetVivo holds 12 U.S. patents and 9 foreign patents, with ongoing efforts to expand this portfolio [3][9]. Distribution and Expansion - **Distribution Agreements**: Established partnerships with major distributors in the U.S. and recent expansions into Mexico and the UK [3][27]. - **Market Growth**: The pet care market is considered recession-proof, with increasing spending on veterinary care as pets are viewed as family members [19]. Clinical Evidence and Studies - **Successful Clinical Trials**: Over 12,000 injections have been administered with positive outcomes, including a study showing a 77% improvement in dogs with late-stage hip issues [10][15][16]. - **Ongoing Research**: Multiple clinical trials are underway, including studies at Colorado State University, aimed at further validating the efficacy of Spryng [16][24]. Future Outlook - **Product Pipeline**: Plans to expand into human markets and develop additional veterinary applications [22][29]. - **Regulatory Support**: The product has received endorsements from regulatory bodies, enhancing its credibility in the market [28]. Management and Team - **Experienced Leadership**: The management team includes individuals with extensive backgrounds in both veterinary and human healthcare sectors, contributing to the company's strategic direction [26][27]. Conclusion PetVivo Holdings is positioned to capitalize on the growing demand for effective veterinary treatments, particularly for osteoarthritis, through its innovative products and strong market presence. The company aims to leverage its unique technology and distribution partnerships to drive future growth and expand into new markets.

Core Points - PetVivo Animal Health, Inc. has entered into a distribution agreement with Nupsala Limited to market its veterinary medical device, Spryng with OsteoCushion technology, in the United Kingdom [1][2] - The distribution activities by Nupsala commenced on September 1, 2025, aiming to enhance the accessibility of Spryng to veterinarians and animal owners [1][2] - Spryng with OsteoCushion technology is designed to manage joint pain in animals by promoting proper joint mechanics and integrating with subsynovial tissue [3][4] Company Overview - PetVivo Holdings, Inc. focuses on the commercialization of innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [5] - The company has a robust pipeline of products, including Spryng and PrecisePRP, and holds a portfolio of twenty-one patents protecting its biomaterials and methods [6] Partner Overview - Nupsala Limited specializes in musculoskeletal health and regenerative medicine for companion animals and horses, operating as both a veterinary wholesaler and referral provider [8][9] - Nupsala aims to improve animal mobility and deliver innovative solutions through clinical trials, diagnostics, and educational initiatives [9]